How Trump's Drug Tariff Threat Is Reshaping the U.S. Pharma Supply Chain
Trump’s tariff plan and MFN pricing shake up the U.S. pharma supply chain. What risks—and opportunities—lie ahead for global manufacturers?
Summary
The Trump administration is taking bold steps to lower U.S. drug prices and impose tariffs on imported pharmaceuticals. But will these policies lead to cheaper drugs—or trigger supply shortages and cost hikes? Here's what industry insiders are preparing for.
